The global diabetes care devices market size was estimated to be USD 59.63 billion in 2023 and is expected to reach at USD 116.53 billion by 2034 with a CAGR of 6.28% during the forecast period 2024-2034. Growing technological advancements, increasing prevalence of obesity & diabetes, rising adoption of insulin delivery devices, surge in technological innovations & development of advanced products, growing demand of diabetes devices, increasing awareness of diabetes, rising geriatric population, and surge in introduction of high-end insulin delivery systems are some of the key factors boosting the market growth.
Surge in introduction of high-end insulin delivery systems is predicted to boost the market growth during the forecast period. In order to reduce the prolonged hospital stays and greater mortality rates among diabetic patients, the need for diabetes devices is rising. Therefore, leading manufacturers are concentrating on technical advancements and the creation of cutting-edge products in order to capture a sizeable portion of the market. For instance, in November 2022, Ypsomed Holding AG has introduced a new automated insulin dosing system called 'my life Loop,' developed in collaboration with CamDiab. This product has received approval for usage in Germany and is designed to work in conjunction with Abbott's FreeStyle Libre 3 sensor for monitoring glucose levels.
By type, insulin delivery devices was the highest revenue-grossing segment in the global diabetes care devices market in 2023 owing to increasing focus on developing innovative devices, growing introduction of small blood glucose meters, and rising initiatives by leading market players. For instance, in September 2023, In Germany, DexCom has launched the integration of the Dexcom G6 Real-Time Continuous Glucose Monitoring System (rt-CGM) with the Omnipod 5 automated insulin delivery (AID) System. Additionally, blood glucose monitoring device is predicted to grow at fastest CAGR during the forecast period owing to the rising adoption of blood glucose meters, increasing collaborations within market players.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global diabetes care devices market in 2023 owing to strong consumer demand & product accessibility, increasing demand for inpatient & outpatient pharmacies, rising demand for insulin delivery devices, and surge in partnerships & collaborations within market players. For instance, in April 2022, Abbott, CamDiab, and Ypsomed have joined forces to establish a collaboration aimed at creating and bringing to market an integrated automated insulin delivery (AID) system across European nations. This technologically linked wearable solution is engineered to constantly track an individual's glucose levels and autonomously fine-tune and administer the appropriate insulin dosage, eliminating the need for uncertain insulin dosing decisions. Additionally, online pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the growing patient awareness regarding online pharmacies and rising funding by market players.
By end-user, hospital was the highest revenue-grossing segment in the global diabetes care devices market in 2023 owing to surge in number of hospital admissions of diabetes patients, increasing adoption of advanced technologies to improve diabetes care in hospitals, rising usage of insulin pumps in hospital & clinics. Additionally, homecare is predicted to grow at fastest CAGR during the forecast period owing to the rising awareness regarding diabetes preventive care, growing government awareness initiatives regarding diabetes & user-friendly insulin pump interface, increasing demand for insulin pumps in homecare settings, surge in launch of advanced blood glucose monitoring systems, and rising collaborations within market players. For instance, in February 2023, Ascensia Diabetes Care, a worldwide diabetes care company known for its CONTOUR® Blood Glucose Monitoring (BGM) system portfolio and exclusive distribution of Eversense® Continuous Glucose Monitoring (CGM) Systems, has unveiled a significant global partnership with SNAQ, an acclaimed app-based solution that provides important dietary insights for individuals with diabetes (PWDs). Through this collaboration and the integration of their technologies, Ascensia and SNAQ aim to enable more PWDs to make informed choices about their meals, ultimately striving to enhance diabetes management.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of obesity, rising adoption of smart devices, growing technological advancements, surge in launch of new products. For instance, in June 2022, Abbott revealed the creation of an innovative system for continuous monitoring of glucose and ketone levels, incorporating a new type of wearable technology. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of insulin delivery devices, rising awareness regarding the diabetes care, surge in healthcare funding, increasing adoption of technologically advanced products, and growing initiatives by major market players. For instance, in May 2023, Roche Diabetes Care India has announced that their popular blood glucose monitoring device, 'Accu-Chek Active,' is now manufactured within India. This decision aligns with the company's strategy to enhance diabetes care accessibility and cater to the increasing demands of the Indian market.
Surge in introduction of high-end insulin delivery systems is predicted to boost the market growth during the forecast period. In order to reduce the prolonged hospital stays and greater mortality rates among diabetic patients, the need for diabetes devices is rising. Therefore, leading manufacturers are concentrating on technical advancements and the creation of cutting-edge products in order to capture a sizeable portion of the market. For instance, in November 2022, Ypsomed Holding AG has introduced a new automated insulin dosing system called 'my life Loop,' developed in collaboration with CamDiab. This product has received approval for usage in Germany and is designed to work in conjunction with Abbott's FreeStyle Libre 3 sensor for monitoring glucose levels.
By type, insulin delivery devices was the highest revenue-grossing segment in the global diabetes care devices market in 2023 owing to increasing focus on developing innovative devices, growing introduction of small blood glucose meters, and rising initiatives by leading market players. For instance, in September 2023, In Germany, DexCom has launched the integration of the Dexcom G6 Real-Time Continuous Glucose Monitoring System (rt-CGM) with the Omnipod 5 automated insulin delivery (AID) System. Additionally, blood glucose monitoring device is predicted to grow at fastest CAGR during the forecast period owing to the rising adoption of blood glucose meters, increasing collaborations within market players.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global diabetes care devices market in 2023 owing to strong consumer demand & product accessibility, increasing demand for inpatient & outpatient pharmacies, rising demand for insulin delivery devices, and surge in partnerships & collaborations within market players. For instance, in April 2022, Abbott, CamDiab, and Ypsomed have joined forces to establish a collaboration aimed at creating and bringing to market an integrated automated insulin delivery (AID) system across European nations. This technologically linked wearable solution is engineered to constantly track an individual's glucose levels and autonomously fine-tune and administer the appropriate insulin dosage, eliminating the need for uncertain insulin dosing decisions. Additionally, online pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the growing patient awareness regarding online pharmacies and rising funding by market players.
By end-user, hospital was the highest revenue-grossing segment in the global diabetes care devices market in 2023 owing to surge in number of hospital admissions of diabetes patients, increasing adoption of advanced technologies to improve diabetes care in hospitals, rising usage of insulin pumps in hospital & clinics. Additionally, homecare is predicted to grow at fastest CAGR during the forecast period owing to the rising awareness regarding diabetes preventive care, growing government awareness initiatives regarding diabetes & user-friendly insulin pump interface, increasing demand for insulin pumps in homecare settings, surge in launch of advanced blood glucose monitoring systems, and rising collaborations within market players. For instance, in February 2023, Ascensia Diabetes Care, a worldwide diabetes care company known for its CONTOUR® Blood Glucose Monitoring (BGM) system portfolio and exclusive distribution of Eversense® Continuous Glucose Monitoring (CGM) Systems, has unveiled a significant global partnership with SNAQ, an acclaimed app-based solution that provides important dietary insights for individuals with diabetes (PWDs). Through this collaboration and the integration of their technologies, Ascensia and SNAQ aim to enable more PWDs to make informed choices about their meals, ultimately striving to enhance diabetes management.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of obesity, rising adoption of smart devices, growing technological advancements, surge in launch of new products. For instance, in June 2022, Abbott revealed the creation of an innovative system for continuous monitoring of glucose and ketone levels, incorporating a new type of wearable technology. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing adoption of insulin delivery devices, rising awareness regarding the diabetes care, surge in healthcare funding, increasing adoption of technologically advanced products, and growing initiatives by major market players. For instance, in May 2023, Roche Diabetes Care India has announced that their popular blood glucose monitoring device, 'Accu-Chek Active,' is now manufactured within India. This decision aligns with the company's strategy to enhance diabetes care accessibility and cater to the increasing demands of the Indian market.
Segmentation: Diabetes Care Devices Market Report 2022 - 2033
Diabetes Care Devices Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
Blood Glucose Monitoring Devices
- Continuous Glucose Monitoring Devices
- Self-Monitoring Devices
Insulin Delivery Devices
- Insulin Pens
- Insulin Pumps
- Insulin Jet Injectors
- Insulin Syringes
Diabetes Care Devices Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Diabetes Clinics/Centers
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Others
Diabetes Care Devices Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Homecare
- Hospitals
- Diagnostic Centers
Diabetes Care Devices Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Diabetes Care Devices Market: Type Estimates & Trend Analysis
8. Diabetes Care Devices Market: Distribution Channel Estimates & Trend Analysis
9. Diabetes Care Devices Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Diabetes Care Devices Market
12. Europe Global Diabetes Care Devices Market
13. Asia Pacific Global Diabetes Care Devices Market
14. Latin America Global Diabetes Care Devices Market
15. MEA Global Diabetes Care Devices Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Johnson & Johnson
- Abbott Laboratories
- Acon Laboratories Inc
- Terumo Corporation
- Becton
- Dickinson and Company
- Medtronic Plc
- Novo Nordisk A/S
- F. Hoffmann-La Roche AG
- Ascensia Diabetes Care
- Medisana
- DexCom Inc.
- AgaMatrix
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 59.63 Billion |
| Forecasted Market Value ( USD | $ 116.53 Billion |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
